Company intelligence / Profile preview

Janux Therapeutics

San Diego, California, USAjanuxrx.com ↗

Ownership: Public · JANX
Development stage: Phase 1

Overview

The company has reported encouraging safety and efficacy data from ongoing Phase I dose escalation trials for its two lead programs: JANX007 targeting PSMA in metastatic castration-resistant prostate cancer, and JANX008 targeting EGFR in multiple solid tumors. Both candidates have demonstrated manageable safety profiles with preliminary signs of anti-tumor activity. Additional TRACTr and TRACIr programs are advancing through discovery or IND-enabling stages.[5][7][4]

Therapeutic areas: Oncology
Modalities: Bispecific antibodiesT cell engagers (TCEs)Immunomodulators
Industry: Biotech

Drug pipeline

8 assets

JANX008

7 more assets in the full pipeline.

Request access →

Financials

Market cap: $1.2B
Total revenue: $10.3M
Enterprise value: $228.9M

Beyond the preview

Go deeper on Janux Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Janux Therapeutics.

Explore the full profile